CN101773507A - 盐酸头孢吡肟/精氨酸药物组合物混悬注射剂 - Google Patents
盐酸头孢吡肟/精氨酸药物组合物混悬注射剂 Download PDFInfo
- Publication number
- CN101773507A CN101773507A CN201010106337A CN201010106337A CN101773507A CN 101773507 A CN101773507 A CN 101773507A CN 201010106337 A CN201010106337 A CN 201010106337A CN 201010106337 A CN201010106337 A CN 201010106337A CN 101773507 A CN101773507 A CN 101773507A
- Authority
- CN
- China
- Prior art keywords
- cefepime hydrochloride
- arginine
- cefepime
- injection
- surfactant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960000927 cefepime hydrochloride Drugs 0.000 title claims abstract description 102
- 239000000725 suspension Substances 0.000 title claims abstract description 61
- 239000004475 Arginine Substances 0.000 title claims abstract description 56
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 title claims abstract description 56
- 238000002347 injection Methods 0.000 title claims abstract description 39
- 239000007924 injection Substances 0.000 title claims abstract description 39
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 28
- LRAJHPGSGBRUJN-OMIVUECESA-N cefepime hydrochloride Chemical compound O.Cl.[Cl-].S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 LRAJHPGSGBRUJN-OMIVUECESA-N 0.000 title claims abstract 24
- 239000000203 mixture Substances 0.000 claims abstract description 32
- 238000002360 preparation method Methods 0.000 claims abstract description 32
- 239000004094 surface-active agent Substances 0.000 claims abstract description 19
- 229920001993 poloxamer 188 Polymers 0.000 claims abstract description 15
- 229940044519 poloxamer 188 Drugs 0.000 claims abstract description 15
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 10
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 10
- 238000004945 emulsification Methods 0.000 claims abstract description 7
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 claims abstract 3
- 239000000839 emulsion Substances 0.000 claims description 17
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 16
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims description 16
- 239000000600 sorbitol Substances 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims description 11
- 235000010262 sodium metabisulphite Nutrition 0.000 claims description 11
- 235000006708 antioxidants Nutrition 0.000 claims description 9
- 239000008215 water for injection Substances 0.000 claims description 9
- 235000010265 sodium sulphite Nutrition 0.000 claims description 8
- 238000012856 packing Methods 0.000 claims description 7
- 238000013019 agitation Methods 0.000 claims description 6
- 238000001694 spray drying Methods 0.000 claims description 6
- 239000012530 fluid Substances 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 238000009413 insulation Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 2
- 235000010323 ascorbic acid Nutrition 0.000 claims description 2
- 229960005070 ascorbic acid Drugs 0.000 claims description 2
- 239000011668 ascorbic acid Substances 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 claims description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 238000005516 engineering process Methods 0.000 abstract description 13
- 238000000034 method Methods 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 11
- 239000002245 particle Substances 0.000 abstract description 10
- 239000003795 chemical substances by application Substances 0.000 abstract description 3
- 238000002156 mixing Methods 0.000 abstract description 3
- 229960003964 deoxycholic acid Drugs 0.000 abstract 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 abstract 1
- MMRINLZOZVAPDZ-LSGRDSQZSA-N (6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methylpyrrolidin-1-ium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;chloride Chemical compound Cl.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 MMRINLZOZVAPDZ-LSGRDSQZSA-N 0.000 description 87
- 235000009697 arginine Nutrition 0.000 description 46
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 16
- 238000012360 testing method Methods 0.000 description 11
- 229960002100 cefepime Drugs 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 9
- 239000000843 powder Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 4
- 229920001983 poloxamer Polymers 0.000 description 4
- 229960000502 poloxamer Drugs 0.000 description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000005374 membrane filtration Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- JFPVXVDWJQMJEE-QMTHXVAHSA-N Cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)C(=NOC)C1=CC=CO1 JFPVXVDWJQMJEE-QMTHXVAHSA-N 0.000 description 2
- 229930186147 Cephalosporin Natural products 0.000 description 2
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 229940124587 cephalosporin Drugs 0.000 description 2
- 150000001780 cephalosporins Chemical class 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N ferric oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 229940021422 maxipime Drugs 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 206010061623 Adverse drug reaction Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005360 mashing Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010101063372A CN101773507B (zh) | 2010-02-05 | 2010-02-05 | 盐酸头孢吡肟/精氨酸药物组合物混悬注射剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010101063372A CN101773507B (zh) | 2010-02-05 | 2010-02-05 | 盐酸头孢吡肟/精氨酸药物组合物混悬注射剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101773507A true CN101773507A (zh) | 2010-07-14 |
CN101773507B CN101773507B (zh) | 2011-11-09 |
Family
ID=42510183
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010101063372A Expired - Fee Related CN101773507B (zh) | 2010-02-05 | 2010-02-05 | 盐酸头孢吡肟/精氨酸药物组合物混悬注射剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101773507B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102743388A (zh) * | 2012-05-15 | 2012-10-24 | 南京优科生物医药有限公司 | 一种抗产生新型β内酰胺酶细菌的组合物 |
CN104610283A (zh) * | 2015-01-30 | 2015-05-13 | 悦康药业集团有限公司 | 一种盐酸头孢吡肟化合物及其药物组合物 |
CN114539289A (zh) * | 2021-10-15 | 2022-05-27 | 广州艾奇西医药科技有限公司 | 头孢吡肟精氨酸聚合物及其制备方法和用途 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100482231C (zh) * | 2007-08-14 | 2009-04-29 | 山东罗欣药业股份有限公司 | 一种盐酸头孢吡肟粉针剂及其制备方法 |
CN101239065B (zh) * | 2008-03-12 | 2011-08-10 | 齐鲁安替制药有限公司 | 盐酸头孢吡肟与l-精氨酸混粉的制备方法 |
CN101332188B (zh) * | 2008-07-11 | 2010-06-30 | 海南数尔药物研究有限公司 | 用超微粉碎技术制备粉针剂的方法及制备的产品 |
CN101623260B (zh) * | 2009-08-24 | 2010-08-18 | 海南美大制药有限公司 | 盐酸头孢吡肟前体脂质体制剂 |
-
2010
- 2010-02-05 CN CN2010101063372A patent/CN101773507B/zh not_active Expired - Fee Related
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102743388A (zh) * | 2012-05-15 | 2012-10-24 | 南京优科生物医药有限公司 | 一种抗产生新型β内酰胺酶细菌的组合物 |
CN104610283A (zh) * | 2015-01-30 | 2015-05-13 | 悦康药业集团有限公司 | 一种盐酸头孢吡肟化合物及其药物组合物 |
CN104610283B (zh) * | 2015-01-30 | 2019-01-11 | 悦康药业集团有限公司 | 一种盐酸头孢吡肟化合物及其药物组合物 |
CN114539289A (zh) * | 2021-10-15 | 2022-05-27 | 广州艾奇西医药科技有限公司 | 头孢吡肟精氨酸聚合物及其制备方法和用途 |
CN114539289B (zh) * | 2021-10-15 | 2023-04-04 | 广州艾奇西新药研究有限公司 | 头孢吡肟精氨酸聚合物及其制备方法和用途 |
Also Published As
Publication number | Publication date |
---|---|
CN101773507B (zh) | 2011-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2734236C2 (ru) | Композиции бендамустина и циклополисахарида | |
CN101264088B (zh) | 一种含量稳定、溶解快速的抗菌素组合物 | |
CN102686217B (zh) | 以类固醇复合物为中间载体的紫杉醇亚微乳 | |
CN101773507B (zh) | 盐酸头孢吡肟/精氨酸药物组合物混悬注射剂 | |
CN101703506B (zh) | 一种美洛西林钠舒巴坦钠药物组合物混悬粉针剂及其新应用 | |
CN102614492B (zh) | 一种含有棘白菌素类抗真菌剂米卡芬净的液体药用组合物 | |
CN101773469B (zh) | 氨曲南/精氨酸药物组合物混悬注射剂 | |
CN104644557A (zh) | 卟啉铁固体分散体及其制备方法 | |
CN101711746A (zh) | 一种注射用更昔洛韦冻干制剂及其制备方法 | |
CN101264063A (zh) | 室温稳定的注射用河豚毒素制剂 | |
CN102525930A (zh) | 一种硫辛酸脂质体注射剂 | |
CN101584661B (zh) | 一种供口服或静脉注射用索拉非尼自微乳化给药系统及其制备方法 | |
CN106176625A (zh) | 注射用拉氧头孢钠的药物组合物 | |
CN102481288A (zh) | 含氨基酸稳定剂的替莫唑胺药物组合物及其制备方法 | |
CN104434803A (zh) | 一种注射用青蒿琥酯和l-赖氨酸组合物及其制备方法 | |
CN104434817B (zh) | 一种利拉鲁肽的注射用缓释微球制剂 | |
CN101693010A (zh) | 一种头孢硫脒前体脂质体制剂 | |
CN108652999A (zh) | 一种儿童牙膏及其制备方法 | |
CN101623260B (zh) | 盐酸头孢吡肟前体脂质体制剂 | |
CN102626381A (zh) | 一种拉氧头孢钠囊泡型磷脂凝胶注射剂 | |
CN102716098B (zh) | 一种头孢妥仑匹酯脂质体固体制剂 | |
CN101376022B (zh) | 含聚乙二醇降纤酶的药物组合物 | |
CN102119929B (zh) | 注射用磺苄西林钠的药物组合物及其制备方法 | |
JP2001261559A (ja) | 高濃度ビタミンc組成物及びその調製方法 | |
CN103690556A (zh) | 一种羟基喜树碱长循环脂质体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: HAINAN LINGKANG PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: WANG MING Effective date: 20130805 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 570125 HAIKOU, HAINAN PROVINCE TO: 570216 HAIKOU, HAINAN PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20130805 Address after: 570216 Hainan Province, Haikou city Jinpan Industrial Development Zone Industrial Village No. 3-6 building Patentee after: Hainan Lingkang Pharmaceutical Co., Ltd. Address before: The new business building No. 48 570125 Hainan city of Haikou province China World Trade Center Road, room 2601 Patentee before: Wang Ming |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20111109 Termination date: 20160205 |